Close Menu

Evotec

The deal comes on the heels of a colorectal cancer-focused drug-discovery alliance that the German companies formed in early 2019.

About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders.

The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing product business around iPSC-derived cells.

Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.

The collaboration will involve Evotec's Panomics platform, which integrates the analysis of genomic, transcriptomic, and proteomic data.


The companies will combine their respective technologies to create a platform for discovering and developing drugs for certain genetic diseases.

The deal expands Evotec's existing CRISPR licenses through the Broad Institute and adds to ERS's list of licensees for its gene editing technology.

Evotec will gain non-exclusive rights to Ncardia IP, including a broad panel of stem cell-derived cell lines for use in drug target discovery and testing.

Thermo Fisher Scientific has qualified global reference laboratories Laboratory Corporation of America and Cancer Genetics to join its Next-Generation Sequencing Companion Dx Center of Excellence Program (COEP).

Evotec will use Merck's collection of genetic reagents — including viral CRISPR and shRNA libraries — in target discovery programs.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.